Core Viewpoint - Ascend Wellness Holdings, Inc. has opened a new dispensary in Englewood, Ohio, expanding its retail presence in the state's regulated cannabis market, catering to both medical and non-medical customers [1][2]. Group 1: Company Expansion - The new dispensary in Englewood is part of Ascend's strategy to enhance its retail footprint in Ohio, where it already operates multiple locations [2]. - Ascend aims to provide safe access and quality products while focusing on a patient- and customer-centric retail experience [2]. Group 2: Grand Opening and Community Engagement - A grand opening event is scheduled for January 16, inviting local patients, customers, and community members to explore the new facility and learn about Ascend's product offerings [3]. - The dispensary is designed to create an efficient and welcoming shopping experience, featuring a variety of cannabis products from leading brands [4]. Group 3: Product Offering and Customer Engagement - The Englewood dispensary will offer a wide range of cannabis products, including flower, vapes, edibles, and concentrates, with options for in-store or online purchases [4]. - Ascend has introduced a revamped loyalty program, the Ascenders Club, to reward customers for their purchases and in-store deals [5]. Group 4: Operational Details - The Englewood dispensary will operate daily from 8:00 a.m. to 11:00 p.m., serving both medical and non-medical customers [6]. - For further information about Ascend and its dispensaries, customers can visit the company's website [6]. Group 5: Company Overview - Ascend Wellness Holdings, Inc. is a vertically integrated cannabis operator with assets across several states, including Ohio, and produces a curated selection of cannabis products for retail and wholesale [7].

Core Insights - The Bloom Brand has launched its Bloom Surf products in Maryland, partnering with gLeaf and The Cannabist Company, just in time for the holiday season [1][2] - The brand emphasizes its commitment to quality and social equity, aligning with Maryland's focus on conscious purchasing and its minority and immigrant-owned roots [2] Company Overview - Bloom was founded in 2014 and has established a reputation for delivering terpene-rich, flavor-forward vape experiences that mimic the sensation of smoking flower, focusing on consistency, quality, and discretion [2] - The Cannabist Company, formerly known as Columbia Care, is a significant player in the cannabis industry, operating 77 facilities across 12 U.S. jurisdictions, including 61 dispensaries and 16 cultivation and manufacturing facilities [2] - The Cannabist Company launched its retail brand Cannabist in 2021, creating a national dispensary network and offering a wide range of cannabis products, including flower, edibles, oils, and tablets [2]

Industry Overview - The cannabis market was valued at $43.72 billion in 2022 and is projected to reach $444.34 billion by 2030, reflecting a CAGR of 34.03% [1] - Global marijuana legalization is gaining momentum, driven by the recognition of its medicinal value and therapeutic uses [1] Company Performance Tilray Brands (TLRY) - Tilray's shares surged 105.5% over the past six months, outperforming Cresco Labs, which gained only 0.3% [4] - In the fiscal first quarter, Tilray's Canadian cannabis revenues rose 4% year over year to $51 million, supported by significant cultivation capacity of approximately 5 million square feet and 210 metric tons of cannabis in production [10] - The company is expanding its medical cannabis footprint in Europe, with plans to triple its German distribution footprint by fiscal 2026 [5][8] - Tilray's international expansion includes a joint venture in Panama and a partnership in Italy to broaden the availability of its medical cannabis extracts [6][7] - The company is also innovating with new product offerings, such as its first medical cannabis edible in Australia [7] Cresco Labs (CRLBF) - Cresco's shares have gained 0.3% over the past six months, indicating slower growth compared to Tilray [4] - The company launched its flagship Cresco-branded flower in Germany, marking its entry into the EU market, which is one of the fastest-growing regulated cannabis markets [12] - Cresco has partnered with a EU GMP-certified manufacturer in Portugal to produce signature flower SKUs, ensuring compliance with European quality standards [13] - Domestically, Cresco holds leading market shares in key states but faces challenges from a tightly regulated and price-compressed market, with revenues declining year over year [15][16] Valuation Comparison - Tilray is trading at a forward 12-month price-to-sales (P/S) ratio of 1.21, above its median of 0.99, while Cresco's forward sales multiple is 0.38, below its one-year median of 0.58 [18] - For fiscal 2026, Tilray's projected loss per share is 5 cents, while Cresco's is projected at 14 cents [21][22] Strategic Positioning - Tilray's established international infrastructure and diversified strategy position it well for capturing long-term value as global cannabis markets evolve [23] - Cresco is taking initial steps into international markets while maintaining solid positions in limited-license U.S. states, using partnerships to mitigate domestic volatility [24]

Core Insights - The ancillary cannabis sector is gaining interest as it navigates a changing landscape, with ancillary operators facing fewer challenges compared to traditional cannabis companies [1][2] - The U.S. cannabis industry continues to grow, with increasing consumer demand and the development of new markets, benefiting ancillary providers [2][3] - Expectations for federal reform could enhance the long-term outlook for ancillary stocks, particularly those involved in real estate and structured lending [3] Summary of Key Companies - **Innovative Industrial Properties (IIPR)**: A specialized real estate investment trust (REIT) that supports regulated cannabis operators through long-term net leases, focusing on cultivation and processing facilities in key states. The company benefits from stable rental agreements and has a conservative financial strategy, maintaining strong cash reserves and manageable debt [5][8] - **NewLake Capital Partners (NLCP)**: Another cannabis-focused REIT that leases to operators across cultivation and retail-support properties. It emphasizes high-quality assets and long-term leases, maintaining a diverse tenant base to balance revenue streams. The company shows steady growth and low leverage, appealing to investors seeking stability [9][11] - **Chicago Atlantic Real Estate Finance (REFI)**: A commercial mortgage REIT that provides senior secured loans to state-licensed cannabis operators. This model allows REFI to capture high-interest income while maintaining collateral control. The company focuses on limited-license states and maintains a disciplined credit approach, generating predictable revenue from interest payments [12][14]

Core Insights - Planet 13 Holdings Inc. reported a significant decline in revenue and increased net loss for Q3 2025, indicating operational challenges and market pressures [4][5][11]. Financial Performance - Q3 2025 revenue was $23.3 million, down 27.6% from $32.2 million in Q3 2024, attributed to price compression and a weaker consumer environment in Nevada, along with increased competition in Florida [5][9]. - The net loss for Q3 2025 was $44.0 million, compared to a net loss of $7.4 million in the same quarter last year, which included a $29.8 million non-cash impairment loss [4][5][9]. - Adjusted EBITDA loss was $4.1 million, a significant decline from an adjusted EBITDA of $1.3 million in Q3 2024, driven by lower gross profit and operating leverage [5][9]. Operational Adjustments - The company has taken decisive actions to address its cost structure, significantly reducing selling, general, and administrative (SG&A) expenses, and has implemented impairment and inventory reserve charges to clean up its balance sheet [2][3]. - Exiting California operations is expected to eliminate a persistent cash drain, allowing the company to focus on Nevada and Florida, where it has competitive advantages [3]. Balance Sheet Overview - As of September 30, 2025, total assets were $158.5 million, down from $206.7 million at the end of 2024, while total liabilities increased to $103.9 million from $94.0 million [6][22]. - Cash reserves decreased to $17.2 million from $23.4 million, indicating liquidity challenges [5][22]. Recent Developments - The company launched a revamped loyalty program and introduced new products in Florida, including HaHa branded fast-acting soft chews [13]. - Planet 13 opened two new dispensaries in Florida and closed its California operations, marking a strategic shift in its market focus [3][13].

Core Insights - Cresco Labs has launched its flagship flower brand in Germany, marking its first entry into the European Union cannabis market [1][2] - The launch is part of Cresco's growth strategy to expand beyond the U.S. cannabis market and gather insights for future international expansion [2][3] Company Strategy - The company aims to leverage its portfolio of market-leading brands and operational capabilities to create value in the European market [3] - Cresco Labs is collaborating with Blossom, its EU GMP-certified manufacturing partner in Portugal, to introduce three signature flower products tailored to specific patient effects [3] Market Context - Germany is recognized as one of the fastest-growing regulated cannabis markets globally, supported by a robust regulatory framework and an increasing patient base [2] - The launch of Cresco products is available via prescription through licensed pharmacies across Germany, indicating a structured approach to market entry [4]

Company Overview - Vireo Growth Inc. has commenced the sale of adult-use cannabis at all eight Green Goods® dispensaries in Minnesota as of September 16, 2025 [1][2] - The company has been operating in Minnesota's medical cannabis market since 2014, serving tens of thousands of patients [2][4] - Vireo aims to expand access, improve product quality, and support the transition to a sustainable adult-use market in Minnesota [2][4] Market Impact - The launch of the adult-use cannabis market in Minnesota, with a population of 5.7 million, is expected to drive strong organic revenue growth for Vireo [1][2] - Vireo is one of the state's licensed adult-use cannabis cultivators and retailers, positioning itself to benefit from the new market dynamics [2][4] Product Offering - Green Goods® dispensaries offer a comprehensive range of medical and adult-use cannabis products, including flower, pre-rolls, edibles, and beverages [3][4] - The dispensaries are strategically located in key areas such as Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury [3] Leadership Commentary - Amber Shimpa, President of Vireo, expressed pride in making products available to all Minnesotans while maintaining commitment to medical patients [3] - Alexandra Breant, Head of Market in Minnesota, highlighted the significance of this milestone in expanding access and building community [3]

Core Viewpoint - MariMed Inc. has entered a strategic agreement with TILT Holdings to expand the distribution of its medical marijuana products in Pennsylvania, aiming to leverage the state's growing market potential [1][2][4]. Group 1: Strategic Agreement Details - MariMed will manage TILT's Standard Farms cultivation and processing facility in Pennsylvania under a Management Services Agreement (MSA) effective September 1, 2025 [2]. - The MSA has an initial term of four years, with MariMed receiving a management fee of 12.5% of Standard Farms' gross revenue [3]. Group 2: Market Expansion and Strategy - The partnership aligns with MariMed's "Expand the Brand" strategy, focusing on becoming a leading consumer packaged goods company in the medical marijuana sector [4]. - Pennsylvania is identified as a strong medical marijuana market with potential for future adult-use cannabis legalization, presenting significant growth opportunities for MariMed [4]. Group 3: Company Profiles - MariMed is recognized for its award-winning cannabis brands, including Betty's Eddies™, Bubby's Baked™, and others, and is committed to quality and innovation in the cannabis industry [5]. - TILT Holdings supports cannabis businesses through a diverse portfolio, including technology and cultivation services, and operates multiple facilities across North America and Europe [6].

Industry Overview - The Canadian cannabis market is gaining investor attention as the U.S. cannabis industry continues to grow rapidly, with legal cannabis sales projected to reach nearly $39 billion in 2024 and potentially exceed $44 billion in 2025 [1] - Despite the growth, federal legalization in the U.S. remains stalled, but several states are advancing their own reform efforts, which is attracting interest in Canadian companies with U.S. exposure [1] Company Highlights - **Tilray Brands Inc. (TLRY)**: - Tilray has expanded significantly in the U.S., owning over 150 dispensaries in key markets like California and Michigan, and has diversified into the wellness and THC-infused beverage sectors [4][7] - The company reported a 13% increase in net revenue to $200 million, with its cannabis segment generating $61 million at a 40% gross margin, and a 132% year-over-year growth in the beverage segment [7] - Although Tilray posted a net loss, it narrowed that loss and achieved an adjusted EBITDA of $9 million, indicating improving fundamentals [7] - **Canopy Growth Corporation (CGC)**: - Canopy operates approximately 120 dispensaries in the U.S. and owns the vaporizer company Storz & Bickel, focusing on both recreational and medical markets [8][10] - The latest quarterly report showed net revenue of around C$66 million, a slight decrease from the previous year, but gross profit rose over 65% to achieve a 35% gross margin [10] - Canopy has cut its total debt by nearly 50% over the fiscal year, reflecting a strong focus on long-term sustainability and operational efficiency [10] - **Cronos Group Inc. (CRON)**: - Cronos has a growing presence in the U.S. with distribution deals supplying products to around 80 dispensaries, focusing on cannabinoid innovation [11][13] - The company reported net revenue of over $32 million, reflecting year-over-year growth, and gross profit rose to $13.7 million due to better cost management [13] - Cronos is investing in research and development to position itself for long-term success in the competitive U.S. market [13] Strategic Insights - The three Canadian cannabis companies—Tilray, Canopy Growth, and Cronos—are strategically expanding their U.S. footprint and improving financial health, making them key players to watch as U.S. legalization discussions continue [14]

Core Insights - Delaware has announced the commencement of adult-use cannabis sales, marking a significant expansion of its cannabis program [1] - MariMed, through its Delaware business unit First State Compassion (FSC), is positioned to lead in this high-growth market due to its decade-long experience and investments [1][4] Company Developments - MariMed has made improvements to its two dispensaries in Wilmington and Lewes to accommodate increased customer traffic from both residents and the nearly 30 million annual tourists [2] - The company is scaling production at its cultivation and processing facilities in Wilmington and Milford to meet rising demand, including popular products like Betty's Eddies chews and its flower brands [3] Industry Context - The leadership of local officials, including State Representative Osienski and State Senator Paradee, has been acknowledged for their role in responsibly growing Delaware's cannabis industry [4] - MariMed is recognized as a leading multi-state cannabis operator with a portfolio of award-winning brands, emphasizing quality and innovation in the cannabis market [4]